CERSSMALL

Cerus Corporation

HealthcareMedical - Devices
$3.28
$0.00(+3.80%)
52W$1.15
$3.47
Updated Jul 7, 02:00 AM
RSI69
RS Rating93/99
Beta1.63
Volatility75%
F-Score5/9
Mkt Cap$657M
STAGE 2 UPTREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

STAGE 2 UPTREND

Cerus Corporation is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 93), indicating clear outperformance against the broad market. Earnings growth of 76% provides fundamental context to the price action. However, price is extended 25% above the 50-day line, increasing the risk of a mean reversion.

Relative Strength
93
out of 99
Market Leader
Trend Score
4/4
Minervini Criteria
STAGE 2 UPTREND
Risk (Beta)
1.63
vs S&P 500
HIGH BETA
52W Position
92%
from 52W low
Near High
Trend & Momentum Analysis

Trend Template (Minervini)

STAGE 2 UPTREND4/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$2.61
50 SMA > 100 SMA$2.32
100 SMA > 150 SMA$2.27
150 SMA > 200 SMA$2.09

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$2.74+19.66%ABOVE
50 SMA$2.61+25.45%ABOVE
100 SMA$2.32+41.39%ABOVE
150 SMA$2.27+44.24%ABOVE
200 SMA$2.09+56.81%ABOVE

Price Performance

1D+3.8%
1W+9.7%
1M+26.2%
3M+77.3%
6M+58.5%
YTD+66.5%
1Y+126.2%
3Y+16.8%
52-Week Trading Range92% from low
$3.28
52W Low$1.15
52W High$3.47

Technical Indicators

RSI (14)BULLISH
69.2
305070
Setup ScoreCOOL
4/10
Base depth: 49.7%

Risk Profile

Beta
1.63
52W Vol
75%
ATR
$0.17
Max DD (1Y)
-38%

Volume Analysis

Today
4.64M
50D Avg
2.86M
Vol Ratio
1.62x
Liquidity
MODERATE

Earnings Momentum

Q2'25+4%
$-0.03
Q3'25+99%
$-0.00
Q4'25+16%
$-0.01
Q1'26+76%
$-0.01
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+19.67%
5 Years:+17.53%
3 Years:+8.35%
TTM:+16.97%

Compounded Profit Growth

10 Years:+17.77%
5 Years:
3 Years:
TTM:+49.61%

Stock Price CAGR

10 Years:-6.47%
5 Years:-9.62%
3 Years:+16.77%
1 Year:+126.21%

Return on Equity

10Y Avg:-71.4%
5Y Avg:-47.6%
3Y Avg:-41.7%
Last Year:-15.2%

Key Metrics

Market Cap$657M
Gross Margin53.5%
Net Margin-7.6%
Piotroski F-Score5/9

Frequently Asked Questions

Is CERS in an uptrend right now?

CERS has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, CERS is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.

Is CERS overbought or oversold?

CERS's RSI (14) is 69. The stock is in neutral territory, neither overbought nor oversold.

Is CERS outperforming the market?

CERS has a Relative Strength (RS) Rating of 93 out of 99. Yes, CERS is a market leader, outperforming 93% of all stocks over the past 12 months.

Where is CERS in its 52-week range?

CERS is trading at $3.28, which is 95% of its 52-week high ($3.47) and 92% above its 52-week low ($1.15).

How volatile is CERS?

CERS has a Beta of 1.63 and 52-week volatility of 75%. It's more volatile than the S&P 500 - expect bigger swings.

Disclaimer: Data is for informational purposes only. May be delayed or contain errors. Past performance does not guarantee future results. This is not financial advice. Always conduct your own research and consult professionals before making investment decisions.